Exabis Library
Welcome to the e-CCO Library!
P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P501: Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P502 Tumour necrosis factor antagonists are superior to anti-integrin and anti-IL-12/23 therapies for preventing postoperative recurrence in adult Crohn’s disease patients requiring postoperative therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P502: Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P502: Dietary habits and nutritional status in children and adolescents with Inflammatory Bowel Disease: an italian multicenter case-control study (NUTRIBD study)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P502: Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P502: Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implications
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P502: Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P503: Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P503: Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P503: Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P503: Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P503: The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P504: Differences between paediatric and adult inflammatory bowel disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM